estenosis is the main limitation of percutaneous coronary intervention (PCI), but the introduction of drug-eluting stents (DES) is a breakthrough development. Clinical trials of DES have reported a markedly decreased rates of restenosis and revascularization compared with bare metal stents (BMS), [1][2][3][4][5][6] but the efficacy of DES in Japanese people is still unclear.Prior to getting approval for the sirolimus-eluting stent (SES: Cypher stent, Cordis Corp, a Johnson&Johnson Company) in Japan, a pharmacokinetic (PK) study evaluating the PKs of sirolimus in Japanese patients and the 1-year clinical outcomes was conducted. 7
Methods
Study SubjectsThe PK study was the first clinical trial of the SES in Japan, and its aim was to evaluate the PKs of sirolimus in Japanese patients and to evaluate early and late clinical outcomes. It was a nonrandomized open trial, comprising 20 patients with 30 lesions who underwent implantation of SES. The patients were all symptomatic and/or had functionally significant de novo native coronary artery disease. Patients were excluded from this study if they had (1) acute myocardial infarction, (2) unstable angina (Braunwald III B, III C), (3) bifurcation lesions, (4) ostial lesions, (5) left main trunk disease, (6) severe calcification, (7) chronic total occlusion, (8) renal dysfunction (serum creatinine >3.0 mg/dl) or liver dysfunction, (9) proximal reference diameter <2.5 mm, (10) allergy to antiplatelet drugs, heparin and sirolimus, (11) extreme bending lesion, (12) left ventricular ejection fraction <25%, (13) cardiac transplantation or (14) another stent within 5 mm of target lesion. The ethical committee at each participating institute approved the protocols, and all patients gave written informed consent.
ProcedureBefore angioplasty, heparin was given intravenously and titrated to maintain an active clotting time more than 250 ms. All patients received a BX velocity stent (3× 18 mm) loaded with a total sirolimus doses of 150 g. All lesions were pre-dilated before stent implantation and adequate post dilatation was performed. All patients received aspirin (200 mg/day indefinitely) and ticlopidine (200 mg/day) from 3 days before the procedure and continued daily for 3 months after SES implantation.
Quantitative Coronary Angiography (QCA)Detailed QCA parameters of the target lesion were evaluated before and after the procedure and at the time of angiographic follow-up using a computer-based system (QCA-CMS 5.1, MEDIS, Leiden, the Netherlands) and an independent observer at Toho University Ohashi Medical Center. This QCA software allows us to also measure automatically all parameters for 5 mm proximal and distal to the stented segment. At the follow-up analysis, in-stent restenosis (ISR) was defined as a diameter stenosis >50% within the stent segment. In-segment restenosis was defined as >50% either within the stented segment or within
Angiographic and Clinical Outcomes of a Pharmacokinetic Study of Sirolimus-Eluting Stents Lesson From Restenosis CasesMasato Nakamura, MD; M...